在进行1型和2型人类免疫缺陷病毒（HIV）联合酶免疫测定筛查后，使用1型和2型HIV重组免疫印迹法来解析抗HIV-2反复反应性的酶免疫测定样本。

Use of human immunodeficiency virus (HIV) type 1 and 2 recombinant strip immunoblot assay to resolve enzyme immunoassay anti-HIV-2-repeatably reactive samples after anti-HIV-1/2 combination enzyme immunoassay screening.

作者信息

Tobler L H, Kaufman E, Gefter N, Schable C, Busch M P

机构信息

Irwin Memorial Blood Centers, San Francisco, California, USA.

出版信息

Transfusion. 1997 Sep;37(9):921-5. doi: 10.1046/j.1537-2995.1997.37997454018.x.

DOI:10.1046/j.1537-2995.1997.37997454018.x

PMID:9308638

Abstract

BACKGROUND

With the implementation of combination human immunodeficiency virus types 1 and 2 (HIV-1/2) antibody enzyme immunoassay (EIA) in donor screening in 1992, the supplemental testing algorithm changed to require the use of a Food and Drug Administration (FDA)-licensed HIV-1 Western blot (WB) or immunofluorescence assay, as well as an FDA-licensed HIV-2 EIA. When HIV-2 EIA-reactive specimens are identified, further testing to confirm HIV-2 infection is recommended. Currently, a licensed HIV-2 supplemental assay is not available.

STUDY DESIGN AND METHODS

The sensitivity of an HIV-1/2 recombinant strip immunoblot assay (SIA) for HIV-2 was determined on the basis of the analysis of 65 HIV-2-positive samples identified by the Centers for Disease Control and Prevention (CDC). Anti-HIV-1/2 combination EIA-repeatably reactive (RR) specimens from seven blood centers and their affiliated hospitals were tested in parallel by HIV-1 WB and HIV-2 EIA. Anti-HIV-2 EIA-RR specimens were further tested by HIV-1/2 SIA. Specimens interpreted as positive for HIV-2 or HIV-1/2 were referred to the CDC for final resolution of antibody status.

RESULTS

Ninety-seven percent (63/65) of known HIV-2-positive samples tested positive for HIV-2 only or HIV-1/2 on the HIV-1/2 SIA. A total of 1048 anti-HIV-1/2 combination-EIA-RR specimens were evaluated. Sixty-nine percent (75/109) of the WB-positive specimens were HIV-2 EIA-RR, while only 9 percent (84/939) of WB-indeterminate or WB-negative specimens tested HIV-2 EIA-RR. The HIV-1/2 SIA resolved 91 percent of HIV-2 EIA-RR samples as negative. Four HIV-2 EIA-RR specimens (all HIV-1 WB-positive) were classified as positive for HIV-1 and HIV-2 in the HIV-1/2 SIA. Final interpretation of these specimens by CDC was that they were reactive for HIV-1 with cross-reactivity to HIV-2.

CONCLUSION

No confirmed HIV-2-positive specimens were detected. The HIV-1/2 SIA is currently useful for resolving HIV-2 EIA-RR specimens.

摘要

背景

随着1992年在献血者筛查中实施人免疫缺陷病毒1型和2型（HIV-1/2）联合抗体酶免疫测定（EIA），补充检测算法改为要求使用美国食品药品监督管理局（FDA）许可的HIV-1免疫印迹法（WB）或免疫荧光测定法，以及FDA许可的HIV-2 EIA。当识别出HIV-2 EIA反应性标本时，建议进一步检测以确认HIV-2感染。目前，尚无许可的HIV-2补充检测方法。

研究设计与方法

基于对疾病控制与预防中心（CDC）鉴定的65份HIV-2阳性样本的分析，确定了HIV-1/2重组条带免疫印迹试验（SIA）对HIV-2的敏感性。来自七个血液中心及其附属医院的抗HIV-1/2联合EIA反复反应性（RR）标本，同时采用HIV-1 WB和HIV-2 EIA进行检测。抗HIV-2 EIA-RR标本进一步采用HIV-1/2 SIA检测。被解释为HIV-2或HIV-1/2阳性的标本送CDC进行抗体状态的最终判定。

结果

97%（63/65）已知HIV-2阳性样本在HIV-1/2 SIA上仅检测为HIV-2阳性或HIV-1/2阳性。共评估了1048份抗HIV-1/2联合EIA-RR标本。69%（75/109）的WB阳性标本为HIV-2 EIA-RR，而WB不确定或WB阴性标本中只有9%（84/939）检测为HIV-2 EIA-RR。HIV-1/2 SIA将91%的HIV-2 EIA-RR样本判定为阴性。4份HIV-2 EIA-RR标本（均为HIV-1 WB阳性）在HIV-1/2 SIA上被判定为HIV-1和HIV-2阳性。CDC对这些标本的最终解释是它们对HIV-1有反应且与HIV-2有交叉反应。